Therapeutic strategies for COVID-19: progress and lessons learned

G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Innate immunity: the first line of defense against SARS-CoV-2

MS Diamond, TD Kanneganti - Nature immunology, 2022 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute
respiratory syndrome coronavirus (SARS-CoV)-2, continues to cause substantial morbidity …

[HTML][HTML] Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA suggest prolonged gastrointestinal infection

A Natarajan, S Zlitni, EF Brooks, SE Vance, A Dahlen… - Med, 2022 - cell.com
Background COVID-19 manifests with respiratory, systemic, and gastrointestinal (GI)
symptoms. 1, SARS-CoV-2 RNA is detected in respiratory and fecal samples, and recent …

Innate immunological pathways in COVID-19 pathogenesis

SR Paludan, TH Mogensen - Science immunology, 2022 - science.org
Coronavirus disease 2019 (COVID-19) is a disease characterized by a profound
dysregulation of the innate immune system. This knowledge has emerged from the large …

Drug treatments for covid-19: living systematic review and network meta-analysis

RAC Siemieniuk, JJ Bartoszko, D Zeraatkar, E Kum… - bmj, 2020 - bmj.com
Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19).
Design Living systematic review and network meta-analysis. Data sources WHO covid-19 …

Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19

SA Lowery, A Sariol, S Perlman - Cell Host & Microbe, 2021 - cell.com
COVID-19 can result in severe disease characterized by significant immunopathology that is
spurred by an exuberant, yet dysregulated, innate immune response with a poor adaptive …

Spheromers reveal robust T cell responses to the Pfizer/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection

F Gao, V Mallajosyula, PS Arunachalam… - Immunity, 2023 - cell.com
T cells are a critical component of the response to SARS-CoV-2, but their kinetics after
infection and vaccination are insufficiently understood. Using" spheromer" peptide-MHC …

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial

JJ Feld, C Kandel, MJ Biondi, RA Kozak… - The Lancet …, 2021 - thelancet.com
Background To date, only monoclonal antibodies have been shown to be effective for
outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate …

Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial

P Gutiérrez-Castrellón, T Gandara-Martí… - Gut …, 2022 - Taylor & Francis
Intestinal bacteria may influence lung homeostasis via the gut-lung axis. We conducted a
single-center, quadruple-blinded, randomized trial in adult symptomatic Coronavirus …

Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses

BL Sievers, S Chakraborty, Y Xue, T Gelbart… - Science translational …, 2022 - science.org
Multiple severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that have
mutations associated with increased transmission and antibody escape have arisen over the …